MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Eli Lilly and Company DSO Ratio 2011-2026 | LLY
Annual DSO Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 80.5 | 81.4 | 85.5 | 86.8 | 80.9 | 77.5 | 90.6 | 92.2 | 84 | 82 | 74.5 | 70.7 | 63.5 | 62.8 | 63.7 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 92.2 | 62.8 | 78.4 |
Quarterly DSO Ratio Eli Lilly and Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.9 | 80 | 85 | 76.3 | 83.5 | 75.3 | 82.6 | 94.5 | - | 44.1 | 44.5 | 75.9 | - | 79.1 | 77.3 | 76.9 | - | 93.4 | 97.5 | 81.2 | 67.9 | 75.8 | 73.6 | 81.9 | 74.4 | 79 | 75.1 | 78.8 | 71.9 | 83.6 | 81.5 | 86.7 | 63.8 | 70.8 | 68 | 70.7 | 59.6 | 64.6 | 64.4 | 66.3 | 57.6 | 60.5 | 59.8 | 65 | 54 | 54.3 | 52.9 | 55.1 | 51.1 | 55.9 | 54.4 | 56.5 | - | 53.4 | 52.5 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 97.5 | 44.1 | 69.9 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Exelixis
EXEL
|
43.4 | $ 46.48 | 4.64 % | $ 12.6 B | USA |
 |
Fortress Biotech
FBIO
|
115 | $ 2.5 | 1.63 % | $ 69.8 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
56.5 | $ 28.79 | 1.41 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.79 | 0.92 % | $ 17.1 B |  Danmark |
 |
Immuron Limited
IMRN
|
148 | $ 0.8 | 1.39 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
20.5 | $ 76.27 | 1.36 % | $ 12.2 B | USA |
 |
Kamada Ltd.
KMDA
|
103 | $ 8.28 | 0.85 % | $ 260 M |  Israel |
 |
Kazia Therapeutics Limited
KZIA
|
28.7 | $ 13.28 | -1.26 % | $ 1.76 B | Australia |
 |
INmune Bio
INMB
|
19.9 K | $ 1.54 | - | $ 38.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 232.25 | -0.02 % | $ 4.25 B | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 41.83 | 4.24 % | $ 3.6 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.89 | 2.42 % | $ 3.79 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 108.2 | 2.26 % | $ 5.43 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
MannKind Corporation
MNKD
|
26.2 | $ 3.84 | 34.27 % | $ 1.17 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.51 | 0.29 % | $ 5.78 M | Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 23.68 | 1.09 % | $ 3.01 B | USA |